SEP 17 2004 SEP

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2005. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449A/B/PTO 10/750,620 Application Number INFORMATION DISCLOSURE December 30, 2003 Filing Date Xiaobing Wu STATEMENT BY APPLICANT First Named Inventor N/A Art Unit (Use as many sheets as necessary) Examiner Name Not Yet Assigned 04577/0200726-US0 Attorney Docket Number Sheet

U.S. PATENT DOCUMENTS							
Examiner Initials*  Cite No.1  Document Number Publication Date Number Applicant of Cited Document  Name of Patentee or Applicant of Cited Document  Pages, Cotumns, Lines, W Relevant Passages or Relevant Pages, Cotumns, Lines, W Relevant Pages, Lines, Line							
					l.,		

		FOREIG	GN PATENT	DOCUMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document  Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>6</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T°

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. At indication of the year of the Imperor must precede the serial number of the patent document. Find of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
195	1.	Pascual M, et al., Strategies To Improve Long-Term Outcomes After Renal Transplantation. N Engl J Med. (2002) 346, 580-90.	
195	2.	Tilney NL, et al., Chronic Rejection. Transplant Proc (1998) 30, 1590-1594.	
195	3.	Libby P and Pober JS, Chronic Rejection. Immunity (2001) 14, 387-397.	
199	4.	Schuller DJ, et al., Crystal Structure Of Human Heme Oxygenase-1. Nat. Structural Biology (1999) 6, 860-867.	
A5	5.	Maines MD, The Hemc Oxygnase System: A Regulator Of Second Messenger Gases. Annu. Rev. Pharmacol. Toxicol. (1997) 37, 517-554.	
195	6.	Otterbein LE, et al., Carbon Monoxide Has Anti-Inflammatory Effects Involving The Mitogen-Activated Protein Kinase Pathway. Nat. Med. (2000) 6, 422-428.	
45	7.	Minamino T, et al., Targeted Expression Of Heme Oxygnase-1 Prevents The Pulmonary Inflemmatory And Vascular Responses To Hypoxia. Proc. Natl. Acad. Sci. USA (2001) 98, 8798-8803.	
145	8.	Amersi F, et al., Upregulation Of Heme Oxygenase-1 Protects Genetically Fat Zucker Rat Livers From Ischemis/Reperfusion Injury. J. Clin. Invest. (1999) 104, 1631-1639.	
795	9.	Yet SF, et al., Cardiac-Specific Expression Qf Heme Oxygenase-1 Protects Against Ischemia	

Examiner	7/	- //r	Date	12-127105
Signature		Just	Considered	10/0/103

PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sui	ostitute for form 1449A/E	R/PTO		Complete if Known			
Su		311 10		Application Number	10/750,620		
11	NFORMATIO	ON DI	SCLOSURE	Filing Date	December 30, 2003		
S	TATEMEN'	T BY	APPLICANT	First Named Inventor	Xiaobing Wu		
	.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,			Art Unit	N/A		
	(Use as many	y sheets as	necessary)	Examiner Name	Not Yet Assigned		
Sheet	2	of	3	Attorney Docket Number	04577/0200726-US0		

	,	2004004004004004004004004004004004004004
		And Reperfusion Injury In Transgenic Mice. Circ. Res. (2001) 89, 168-173.
19	10.	Soares MP, et al., Expression Of Heme Oxygenase-1 Can Determine Cardiac Xenograft Survival. Nat. Med. (1998) 4, 1073-1077.
145	11.	Debruyne LA, et al.,. Gene Transfer Of Immunomodulatory Peptides Correlates With Heme Oxygenase-1 Induction And Enhanced Allograft Survival. Transplantation (2000) 69, 120-128.
<u>.</u> 45	12.	Hancock WW, et al., Antibody-Induced Transplant Arteriosclerosis Is Prevented By Graft Expression Of Anti-Oxidant And Anti-Apoptosic Genes. Nat. Med. (1998) 4, 1392-1396.
195 195	13.	Zhijian WU, et al., Generation Of A Recombinant Herpes Simplex Virus Which Can Provide Packaging Function For Recombinant Adeno-Associated Virus. Chinese Science Bulletin (1999) 44, 715-718.
45	14.	Xiobing WU, et al., A Novel Method For Purification Of Recombinant Adeno-Associated Virus Vectors On A Large Scale. Chinese Science Bulletin (2001) 46, 484-489.
135	15.	Samulski RJ, et al., Helper-Free Stocks Of Recombinant Adeno-Associated Viruses: Normal Integration Does Not Require Viral Gene Expression. J. Virol. (1989) 63, 3822-3828.
PS	16.	Demetris AJ, et al., Analysis of Chronic Rejection and Obliterative Arteriopathy Am. J. Pathol. (1997) 150, 563-578.
	17.	Border WA and Nobel NA, <i>Transforming Growth Factor-β In Tissue Fibrosis</i> . N. Engl. J. Med. (1994) 331, 1286-1292.
45 #5	18.	Kaplitt MG, et al., Long-Term Gene Expression And Phenotypic Correction Using Adeno Associated Virus Vectors In The Mammalian Brain. Nat. Genet. (1994) 8, 148-154.
45	19.	Owens RA, et al., Second Generation Adeno-Associated Virus Type 2-Based Gene Therapy Systems With The Potential For Preferential Integration Into AAVS1. Curr. Gene Ther. (2002) 2, 145-159
195	20.	Brouard S, et al., Carbon Monoxide Generated By Heme Oxygenase 1 Supresses Endothelial Cell Apoptosis. J. Exp. Med. (2000) 192, 1015-1025.
35	21.	Lee TS and Chau LY, Heme Oxygnnse-1 Mediated The Anti-Inflammatory Effect Of Interleukin-10 In Mice. Nat. Med. (2002) 8, 240-246.
195	22.	Duckers HJ, et al., Heme Oxygenase-1 Protects Against Vascular Constriction and Proliferation. Nature Medicine (2001) 7, 693-698.
<u>-</u> 45	23.	Peyton KJ, et al., Heme Oxygenase-1 Derived Carbon Monoxide Is An Autocrine Inhibitor Of Vascular Smooth Muscle Cell Growth. Blood (2002) 99, 4443-4448.
·/	ــــــــــــــــــــــــــــــــــــــ	

Examiner Signature	116	- Syla	Date Considered	12/27/05
<u> </u>				

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE spond to a collection of information unless it contains a valid OMB control number.

Sub	stitute for form 1449A/B	VPTO		Complete if Known		
500	isulate for form 1440746			Application Number	10/750,620	
IN	IFORMATIC	ON DI	SCLOSURE	Filing Date	December 30, 2003	
S	TATEMENT	BY	APPLICANT	First Named Inventor	Xiaobing Wu	
				Art Unit	N/A	
	(Use as many	sheets as	necessary)	Exeminer Name	Not Yet Assigned	
Sheet	3	of	3	Attorney Docket Number	04577/0200726-US0	

195	24.	Tulis DA, et al., Adenovirus-Mediated Heme Oxygenase-1 Gene Delivery Inhibits Injury-Induced Vascular Neointima Formation. Circulation (2001) 104, 2710-2715.	
145	25.	Liu X, et al., Adenovirus-Mediated Heme Oxygenase-1 Gene Expression Stimulates Apoptosis In Vascular Smooth Muscle Cells. Circulation (2002) 105, 79-84.	
195	26.	Waltenberger J, et al., Induction Of Transforming Growth Factor-β During Cardiac Allograft Rejection. J. Immunol. (1993) 151, 1147-1157.	
14	27.	Little DM, et al., Does Transforming Growth Factor β 1 Play A Role In The Pathogenesis Of Chronic Allograft Rejection? Transpl. Int. (1999) 12, 393-401.	
14	28.	Pascual M, et al., Chronic Rejection And Chronic Cyclosporin Toxicity In Renal Allografts. Immunol. Today (1998) 19, 514-519.	
13.5	29.	Fujita T, et al., Paradoxical Rescue From Ischemic Lung Injury By Inhaled Carbon Monoxide Driven By Derepression Of Fibrinolysis. Nat. Med. (2001) 7, 598-604	
195	30.	Shibahara S, et al., Cloning And Expression Of cDNA For Rat Heme Oxygenase. Proc. Natl. Acad. Sci. USA (1985) 82:7865-7869.	
135	31.	Ono K and Lindsay ES, Improved Technique Of Heart Transplantation In Rats. J. Thorac. Cardiovasc. Surg. (1969) 57:225.	
145	32.	Tsui TY, et al., Prevention Of Chronic Deterioration Of Heart Allograft By Recombinant Adeno- Associated Virus-Mediated Heme Oxygenase-1 Gene Transfer. Circulation (2002) 2623-2629.	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner Signature	Mr	- has	Date Considered	12127/05

<sup>&</sup>lt;sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.